Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I drug-drug interaction study of Veltassa (patiromer) with lithium in healthy volunteers

Next Previous
Search
Trial Profile

Phase I drug-drug interaction study of Veltassa (patiromer) with lithium in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patiromer (Primary) ; Lithium
  • Indications Hyperkalaemia
  • Focus Pharmacokinetics
  • Sponsors Relypsa

    • Most Recent Events

    • 13 Feb 2017 According to a Relypsa media release, results from this study were published in the Journal of Cardiovascular Pharmacology and Therapeutics.
    • 25 May 2016 According to a company media release, Relypsa submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa (patiromer) for oral suspension based on results of this and other Phase 1 drug-drug interaction studies in healthy volunteers.
    • 29 Feb 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top